Automated radiosynthesis of [18F]AlF-NOTA-octreotide and PET/CT imaging in NENs

[F-18]AlF-NOTA-octreotide was evaluated for its biodistribution and dosimetry and demonstrated good safety, good tolerance, in vivo pharmacokinetics, and specific uptake in somatostatin receptor 2 (SSTR2)-positive tumors. This study aimed to improve the automated radiolabeling of NOTA-octreotide with [F-18]AlF2+ and optimize the radiochemical yield (RCY) of [F-18]AlF-NOTA-octreotide. The labeling procedure was optimized by changing the amounts of peptide and AlCl3, the labeling buffers. To simplify the process of preparing the solution, the reagent of the precursor (NOTA-octreotide 0.2 mg) and AlCl3 center dot 6H(2)O (27 mu L 4 mM) were made into freeze-dried kit in advance. NOTA-octreotide was labeled with [F-18]AlF2+ with a 55% yield in 40 min. This method can be used to effectively improve RCY and meet clinical requirements.

Automated summary

The study improved the automated radiolabeling of [F-18]AlF-NOTA-octreotide and optimized the radiochemical yield, showing specific uptake in SSTR2-positive tumors and meeting clinical requirements.